Viracta Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch VIRX and buy or sell other stocks, ETFs, and their options commission-free!

About VIRX

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. 

CEO
Craig R. Jalbert
CEOCraig R. Jalbert
Employees
40
Employees40
Headquarters
Cardiff, California
HeadquartersCardiff, California
Founded
1998
Founded1998
Employees
40
Employees40

VIRX Key Statistics

Market cap
643.86K
Market cap643.86K
Price-Earnings ratio
-0.01
Price-Earnings ratio-0.01
Dividend yield
—
Dividend yield—
Average volume
172.32K
Average volume172.32K
High today
$0.0175
High today$0.0175
Low today
$0.0154
Low today$0.0154
Open price
$0.0175
Open price$0.0175
Volume
31.73K
Volume31.73K
52 Week high
$0.58
52 Week high$0.58
52 Week low
$0.008
52 Week low$0.008

People also own

Based on the portfolios of people who own VIRX. This list is generated using Robinhood data, and it’s not a recommendation.
Zomedica
SNDL
Tonix Pharmaceuticals
Ocugen, Inc
Tilray Brands
Workhorse
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.